Nck modulators are a new class of oral small molecules that inhibit Nck from binding to the T cell receptor (or TCR),blocking TCR activation to treat autoimmune diseases without causing immunosuppression. Christopher VanDeusen, PhD, Chief Scientific Officer of Artax Biopharma, explains how this new approach may help treat a panoply of dermatologic diseases. He also shares preclinical findings presented at the 2025 American Academy of Dermatology’s annual meeting in Orlando, FL.
